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Background: Data are limited regarding routine use of everolimus after initial vascular endothelial growth factor
(VEGF)–targeted therapy. The aim of this prospective, noninterventional, observational study was to assess efficacy
and safety of everolimus after initial VEGF-targeted treatment in patients with metastatic renal cell carcinoma
(mRCC) in routine clinical settings.
Methods: Everolimus was administered per routine clinical practice. Patients with mRCC of any histology from 116
active sites in Germany were included. The main objective was to determine everolimus efficacy in time to
progression (TTP). Progression-free survival (PFS), treatment duration, tumor response, adherence to everolimus
regimen, treatment after everolimus, and safety were also assessed.
Results: In the total population (N = 334), median follow-up was 5.2 months (range, 0–32 months). Median treatment
duration (safety population, n = 318) was 6.5 months (95% confidence interval [CI], 5–8 months). Median TTP and
median PFS were similar in populations investigated. In patients who received everolimus as second-line treatment
(n = 211), median (95% CI) TTP was 7.1 months (5–9 months) and median PFS was 6.9 months (5–9 months). Commonly
reported adverse events (safety population, n = 318) were dyspnea (17%), anemia (15%), and fatigue (12%). Limitations of
the noninterventional design should be considered.
Conclusions: This study reflects routine clinical use of everolimus in a large sample of patients with mRCC. Favorable
efficacy and safety were seen for everolimus after previous therapy with one VEGF-targeted agent. Results of this study
confirm everolimus as one of the standard options in second-line therapy for patients with mRCC. Novartis study code,
CRAD001LD27: VFA registry for noninterventional studies (http://www.vfa.de/de/forschung/nisdb/).
Keywords: Observational study, Everolimus (RAD001), Carcinoma, Renal cell, Targeted molecular therapyBackground
In the European Union, the mammalian target of rapamy-
cin (mTOR) inhibitor everolimus (Afinitor; Novartis,
Basel, Switzerland) is registered for treatment of patients
with metastatic renal cell carcinoma (mRCC) after failure
of a previous vascular endothelial growth factor (VEGF)–
targeted agent (VEGF antibody or VEGF receptor-tyrosine
kinase inhibitor [VEGFR-TKI]) [1]. Approval was based* Correspondence: L.Bergmann@em.uni-frankfurt.de
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unless otherwise stated.on results of the phase 3 RECORD-1 study in which
everolimus significantly improved median progression-
free survival (PFS) compared with placebo (4.9 vs.
1.9 months; hazard ratio [HR], 0.33; p < .001) in patients
who previously received sunitinib, sorafenib, or both
(previous cytokines and/or bevacizumab also permitted);
21% of patients previously received one medication before
everolimus [2]. A subgroup analysis of RECORD-1
showed numerically longer median PFS in patients who
previously received only one VEGFR-TKI than in patients
who previously received two VEGFR-TKIs (5.4 and
4.0 months, respectively) [3]. Median PFS of patients whotral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatment was 4.6 months with everolimus (n = 43) and
1.8 months with placebo (n = 13) (hazard ratio [HR], 0.22;
p < .001) [3]. RECORD-1 showed a favorable tolerability
profile for everolimus, with a low rate of grade 3 or 4 ad-
verse events (AEs) and low rates of dose modification (7%)
and treatment discontinuation because of AEs (13%)
[2]. Results of the international, open-label, expanded-
access program REACT were consistent with results of
RECORD-1 and showed that everolimus was well toler-
ated and provided clinical benefit (52% stable disease)
in VEGFR-TKI–refractory patients with mRCC [4].
A recently published retrospective analysis investigated
the efficacy of sequential VEGFR-TKI, VEGFR-TKI, and
mTOR inhibitor and of sequential VEGFR-TKI, mTOR
inhibitor, and VEGFR-TKI in Italy [5]. Median PFS
ranged from 36.5 to 29.3 months, and median overall
survival (OS) ranged from 50.7 to 37.8 months. The
study was performed in a nonrandomized, retrospective
setting based on a highly selected patient population
(only 13% of all treated patients had received three lines
of targeted therapy). Because of potential immortal time
bias for results of second-line treatment, this study did
not meet the requirements for inclusion in a meta-
analysis of adjusted, multicenter, retrospective cohort
studies, which showed that OS was significantly pro-
longed in VEGFR-TKI–refractory patients with mRCC
treated with a second-line mTOR inhibitor compared
with a second-line VEGFR-TKI (HR, 0.82; 95% confi-
dence interval [CI], 0.68–0.98) [6]. Although these stud-
ies and analyses added insight into sequential treatment
options for patients with mRCC, data regarding the rou-
tine use of everolimus in second-line therapy after initial
VEGF-targeted therapy still are limited. Therefore, this
noninterventional study assessed the efficacy and safety
of everolimus after initial VEGF-targeted therapy in




This was a prospective, observational study conducted at
166 registered sites. Patients with mRCC (clear cell or
non–clear cell) were enrolled when the physician
intended to treat them with everolimus after failure of
one VEGF-targeted therapy (VEGFR-TKI or bevacizu-
mab). To ensure mainly prospective observation, retro-
spective enrollment was limited to patients who had
begun treatment with everolimus up to 90 days before
the start of the study or had undergone no more than
one image-based follow-up since treatment initiation.
Everolimus was administered according to the approved
product label in Europe [7]. Patients received everolimus
10 mg once daily until disease progression or unacceptabletoxicity. Dose interruptions, reductions to 5 mg/day, or
both were used, if necessary, to manage side effects.
The study was performed in accordance with German
drug law and relevant guidelines of the German health
authorities and the pharmaceutical industry for conduct-
ing noninterventional studies. The ethics committee of
the Johann Wolfgang Goethe-University Frankfurt am
Main, which was constituted according to state law and
bears responsibility for the medical leader of this study,
granted approval of the observational plan. Patients pro-
vided written informed consent before the start of the
study.
Aim and objectives
The aim of the study was to estimate the efficacy and
safety of everolimus after the first anti-VEGF agent in
routine clinical practice. The main objective was to de-
termine everolimus efficacy in terms of time to pro-
gression (TTP; time between baseline and progression
based on physician assessment). In addition, PFS (time
between baseline and progression or death based on
physician assessment or death from any cause) was
assessed. Patients who did not experience progression
and who did not die during the observation period were
censored at study discontinuation; patients without a
documented study discontinuation date were censored at
the analysis cutoff date. Other objectives included treat-
ment duration, tumor response, adherence to everolimus,
posteverolimus treatment, and safety.
Assessments
Evaluation of treatment response and progression was
based on physician assessment (i.e., on clinical judgment
and/or imaging results; Response Evaluation Criteria In
Solid Tumors [RECIST] evaluation was possible but not
mandatory). In accordance with routine practice, docu-
mentation of the following observation parameters was
aimed for regular visits, in line with routine practice
(e.g., after approximately 3-month intervals): assessment
of the response to treatment (computed tomography/mag-
netic resonance imaging (CT/MRI), skeletal scintigraphy,
positron emission tomography (PET)/PET-CT, ultra-
sound) and/or clinical assessment of the patient’s status.
Kaplan-Meier statistics were applied for analysis of treat-
ment duration, TTP, PFS, and time to worsening of
Karnofsky performance status (KPS); in cases of descrip-
tive comparisons of such parameters, the log-rank test
was used. For all other parameters, descriptive statistics
were applied. AEs were collected and coded to a preferred
term using the Medical Dictionary for Regulatory Activ-
ities (MeDRA). According to the methodological features
of an observational noninterventional study, all statistical
analyses were descriptive, and the presented results should
be interpreted as such.
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The study was planned to enroll 360 patients; at the
end of observation, 334 patients had been enrolledFigure 1 CHANGE patient disposition. VEGFR-TKI, vascular endothelial grow
per patient. bAdverse event and death were reasons for discontinuation fo(Figure 1). The first interim analysis was based on all
patients with ≥3 months of documented evaluation or
discontinuation and included 113 patients (medianth factor receptor–tyrosine kinase inhibitor. aMore than one reason
r four patients.
Table 1 Baseline characteristics
Characteristics Total population (N = 334)




Tumor histology, n (%)
Clear cell 293 (88)
Non–clear cell 24 (7)
Missing 17 (5)
KPS, median (range) 80 (50–100)
Time since diagnosis, median (range), y
Initial 3.3 (0–34)
Metastasis 1.7 (0–16)




Primary metastatic site, n (%)b
Lung 226 (68)
Lymph node 145 (43)
Skeletal system 125 (37)
Liver 87 (26)
Adrenal gland 47 (14)
Previous surgery, n (%) 325 (97)
Previous nephrectomy 300 (90)




Abbreviations: MSKCC, Memorial Sloan-Kettering Cancer Center; KPS, Karnofsky
performance status.
a100% relate to patients with documented evaluation (n = 238).
bPatients could have had multiple metastatic locations.
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was performed after patients from the first analysis were
followed up for another 10 months and included those
patients plus patients who had entered the trial at this
stage (N = 196; median observation, 4.7 months) [9].
The total population included all patients who were
enrolled at baseline. The safety population included all
patients from the total population who had docu-
mented evidence of everolimus intake and one or more
postbaseline assessments. The efficacy population in-
cluded all patients from the safety population who were
enrolled ≤90 days after the initiation of treatment and
who received a single VEGF-targeted therapy (VEGFR-
TKI or bevacizumab); a second VEGFR-TKI was allowed
for <1 month before everolimus. The population receiving
everolimus after receiving exactly one previous VEGF-
targeted therapy (i.e., everolimus in second line) included
patients from the efficacy population who previously re-
ceived exactly one VEGF-targeted agent (Figure 1).
Results
Patients and treatment duration
The observation period was from August 17, 2009, to
January 18, 2013. The total population was composed of
334 patients enrolled at 116 active sites. The safety
population included 318 patients, the efficacy population
included 280, and the population receiving everolimus
as second-line treatment included 211 (Figure 1). Among
patients in the total population (multiple items possible
per patient), there was no further documented evaluation
after baseline for 15 patients, 1 did not receive everolimus,
12 exceeded the allowed retrospective enrollment time
frame, and 31 exceeded the permitted VEGFR-TKI pre-
treatment. In the total population, median follow-up was
5.2 months (range, 0–32 months); median follow-up time
under treatment was 22.4 months (range, 12–41 months)
for 78 patients still receiving treatment at the end of
observation.
Median patient age was 68 years (range, 22–89 years),
and median KPS at baseline was 80% (range, 50–100%)
(Table 1). Of the patients, 75% were men, 88% had clear
cell histology, and 92% had favorable/intermediate
Memorial Sloan-Kettering Cancer Center (MSKCC) risk
(at first-line therapy). Most patients (72%) previously re-
ceived only one systemic therapy. The most common pre-
vious targeted agent was sunitinib (78%), for which median
treatment duration was 9 months (range, 0–63 months)
(Table 2). In the overall population, 86% of patients
switched from their previous therapy to everolimus be-
cause of progression, and 14% switched because of other
reasons (e.g., intolerance or patient request).
Among patients who were evaluated at visits 2–6 and
for whom data were accessible, imaging was used in at
least 46% and at most 73% of patients per visit in thesafety population and in at least 40% and at most 72% of
patients per visit in the efficacy population. Likewise,
during visits 2–6, RECIST criteria were applied to at
least 46% and at most 63% of patients per visit in the
safety population and in at least 25% and at most 59% of
patients per visit in the efficacy population.
In the safety population, 138 patients discontinued be-
cause of progression and, of those patients, progression
was documented by imaging in 81%. Similarly, among
115 patients in the efficacy population who discontinued
because of progression, imaging documented progression
in 78%.
Median duration of everolimus treatment was 6.5 months
(95% CI, 5–8 months; mean dose intensity, 94%) in the
safety population (Figure 2), 6.6 months (95% CI,
Table 2 Previous therapy, targeted agents, and cytokines
(total population, N = 334)
Previous therapya Patients, n (%) Duration of treatment,b
median (range), mo
Sunitinib 260 (78) 9 (0–63)
Sorafenib 68 (20) 6 (0–48)
Pazopanib 12 (4) 3 (1–11)
Bevacizumabc 41 (12) 6 (0–29)
Cytokinesd 33 (10) 8 (0–113)
aPatients could have received multiple previous therapies.
bDuration was calculated for patients with information on duration (sunitinib,
n = 251; sorafenib, n = 65; pazopanib, n = 12; bevacizumab, n = 41;
cytokines, n = 33).
cGiven as monotherapy in 14 patients and as part of combination therapy in
27 patients.
dCombination of cytokines and bevacizumab was included in the
bevacizumab category.
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(95% CI, 5–9 months) in the population receiving everoli-
mus as second-line treatment.
Efficacy
Median TTP was 7.0 months (95% CI, 6–9 months) in
the safety population, 7.4 months (95% CI, 6–9 months)
in the efficacy population, and 7.1 months (95% CI,
5–9 months) in the population of patients who received
everolimus as second-line treatment (Figure 3A). Similar
to TTP, median PFS was 6.9 months (95% CI,
5–9 months) in the population of patients who received
everolimus as second-line treatment; (Figure 3B). BestFigure 2 Duration of everolimus treatment in the safety population (n = 31overall response (efficacy population, 217 patients with
assessable data) was remission in 13.8% of patients,
stable disease in 57.1%, and disease progression in
29.0%.
Safety
Adverse events that occurred in ≥5% of patients in the
safety population and the corresponding rate of serious
AEs are shown in Table 3. The most commonly reported
AEs were dyspnea (17%), anemia (15%), and fatigue
(12%). Pneumonitis occurred in 4% of patients (n = 14).
Twenty-seven percent (n = 85) of patients required dose
adjustment, and 20% (n = 63) required dose interruption
(median duration, 14 days [range, 2–90 days]). Median
time to worsening of KPS by ≥10% from baseline was
8.4 months (95% CI, 6–10 months) overall, not reached
(NR; 95% CI, 9 months–NR) for patients with remission,
9.3 months (95% CI, 7–12 months) for patients with
stable disease, and 4 months (95% CI, 3–6 months) for
patients with progression (Figure 4). Among patients in
the safety population, 18% (n = 57) died. AEs potentially
related to study treatment were observed in 11 patients
who died. However, in nine patients, a tumor-related
cause of death was documented; one patient died of
acute myocardial infarction; and one died of acute renal
failure.
End of treatment
At the time of analysis, 78 patients (23%) of the total
population were receiving everolimus and 256 patients8). CI, confidence interval.
Figure 3 TTP (A) and PFS (B) (population of patients receiving everolimus as second-line treatment, n = 211). PFS, progression-free survival; TTP,
time to progression.
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mon reasons for treatment discontinuation were disease
progression (54%), AEs (21%), and death (14%) (See sup-
plementary materials for reasons for disconnection of
study treatment [Additional file 1: Table S1]). Among
patients who discontinued treatment, 123 (48%) received
subsequent therapy, most commonly sorafenib (36%),sunitinib (24%), or pazopanib (21%). Of patients who
died (n = 57, safety population), AEs potentially related
to study treatment were observed in 11 patients; how-
ever, in nine of these cases, a tumor-related cause of
death was documented. Reported causes of death for
two patients were acute myocardial infarction and acute
renal failure.
Table 3 Adverse events irrespective of suspected
causality with everolimus that occurred in ≥5% of
patients (safety population, n = 318)




Overall 224 (70) 125 (39)
Dyspnea 54 (17) 31 (10)
Anemia 46 (15) 21 (7)
Fatigue 37 (12) 13 (4)
Cough 33 (10) 19 (6)
Nausea 28 (9) 6 (2)
Pain 24 (8) 6 (2)
General physical health deterioration 23 (7) 19 (6)
Stomatitis 22 (7) 4 (1)
Peripheral edema 21 (7) 10 (3)
Mucositis 19 (6) 1 (<1)
Pyrexia 19 (6) 11 (4)
Rash 18 (6) 4 (1)
Decreased appetite 17 (5) 1 (<1)
Diarrhea 16 (5) 5 (2)
Decreased weight 16 (5) 4 (1)
aDisease progression was collected as an adverse event according to the
requirement of observational plan. Progression-related events (neoplasm
progression, malignant neoplasm, malignant neoplasm progression) were
summarized under the preferred term “neoplasm progression”. Neoplasm
progression was reported as an adverse event for 57 patients (18%) and as
a serious event for 54 patients (17%).
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Median TTP of everolimus treatment in second-line
treatment after sunitinib (efficacy population, n = 188)
was 7.1 months (95% CI, 5–9 months). Longer duration
of previous VEGF-targeted therapy (VEGFR-TKI or
bevacizumab) tended to result in longer median TTP
with second-line everolimus; however, no statistically
significant differences were observed (Table 4). (See
supplementary materials for treatment duration, TTP,
and PFS by MSKCC risk [Additional file 1: Table S2]
and histology [Additional file 1: Table S3].)
Discussion
Current guidelines recommend second-line everolimus
and axitinib after previous VEGFR-TKI therapy as a
standard treatment option for patients with clear cell
mRCC [10-12]. Although sequential therapy is the
current standard of care, the optimal sequence has not
been established. For example, results of the AXIS and
INTORSECT trials showed clinical benefit of a second-
line VEGFR-TKI in patients for whom first-line
sunitinib was ineffective. In AXIS, second-line median
PFS was 4.8 months for axitinib and 3.4 months for so-
rafenib in patients previously treated with sunitinib
[13]; the corresponding median OS was 15.2 monthsfor axitinib and 16.5 months for sorafenib [14]. In
INTORSECT, second-line median PFS and OS were 3.9
and 16.6 months, respectively, in the sorafenib arm
[15]. In addition, results of the SWITCH trial showed
comparable median PFS (including first-line and
second-line treatment; range, 12.5–14.9 months) and
median OS (range, 30.2–31.5 months) for first-line su-
nitinib followed by sorafenib and first-line sorafenib
followed by sunitinib [16]. Conversely, results of the
large phase 2 trial RECORD-3, which investigated suniti-
nib followed by everolimus compared with the opposite
sequence, support the treatment sequence of first-line
sunitinib followed by second-line everolimus with a me-
dian combined PFS (including first-line and second-line
treatment) of 25.8 months and a median OS of
32.0 months [17]. Taken together, results of these clinical
trials indicate that the optimal sequence of targeted
therapy must still be determined. Results of these
clinical trials influence the interpretation of results of
noninterventional studies, which are important for
assessing sequentially administered targeted therapy in
the daily routine setting. In addition, evidence of the
clinical benefit of sequential VEGFR-TKI, mTOR in-
hibitor, and VEGFR-TKI therapy is increasing [18,19].
In the current study, median PFS was 6.9 months for
patients who previously received exactly one VEGF-targeted
agent and was 7.0 months for patients who previously re-
ceived sunitinib only. In RECORD-1, median PFS was
4.9 months for the overall population [2] and 5.4 months
for patients who previously received one VEGFR-TKI [3].
Although CHANGE was a noninterventional study with
limitations inherent to its noninterventional character
(assessment times according to daily practice; clinical
response assessment allowed, RECIST evaluation not
mandatory), treatment duration, deterioration of KPS,
response, and TTP/PFS showed a high level of consistency,
reflecting clinically relevant outcomes and clinical reality.
Longer duration of first-line therapy seems to corres-
pond with improved effectiveness of second-line targeted
agents. In the current study, second-line everolimus
treatment resulted in favorable efficacy, with a median
TTP of 6.8–8.2 months in patients with shorter or
longer pretreatment duration. However, the longest median
TTP (8.2 months) was observed in patients in whom
pretreatment duration was longest (≥9 months). The
current study results are in line with those of an AXIS sub-
group analysis, which showed a trend toward longer PFS
for patients who received axitinib after ≥9 months of suniti-
nib [20]. Moreover, longer first-line treatment with suniti-
nib or cytokines resulted in longer OS during second-line
treatment with axitinib or sorafenib [20]. The reason for
this potential correlation between previous treatment dur-
ation and second-line efficacy is not known. However, it
seems plausible that longer first-line treatment duration
Figure 4 Time to worsening of Karnofsky performance status by ≥10% by best overall response (safety population). Remission, n = 29; stable
disease, n = 124; disease progression, n = 68.
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to second-line therapy. Although the current study results
suggest a correlation between longer previous treatment
duration and everolimus efficacy, they also show that
everolimus is effective regardless of first-line therapy
duration.
Results of RECORD-1 and REACT showed that evero-
limus is well tolerated in patients with mRCC after inef-
fective VEGF-targeted therapy [2,4]. The safety profile of
everolimus observed in the current study in routineTable 4 Median treatment duration, median TTP, and median
targeted treatment (efficacy population)
Previous VEGF-targeted treatment Treatment dur
Duration, months
<3 (n = 54) vs. ≥3 (n = 203) 6.6 (3–10)
7.1 (5–9)
<6 (n = 105) vs. ≥6 (n = 152) 6.6 (4–9)
7.5 (5–11)
<9 (n = 133) vs. ≥9 (n = 124) 6.6 (4–9)
7.5 (5–11)
Abbreviations: CI, confidence interval; PFS, progression-free survival; TTP, time to pr
p value determined using log-rank test.conditions was manageable and consistent with that of
previous reports.
Limitations of the noninterventional design should be
considered. Data validation by site monitoring visits oc-
curred in 32% of the total population. We assume this
rate is higher than the rate in many other comparable
noninterventional studies, leading to higher documenta-
tion quality. However, the rate is lower than the rate in
interventional trials, leading to lower data quality in
comparison with this type of design. In addition, becausePFS of everolimus by duration of previous VEGF-
ation TTP PFS
Median, months (95% CI)
7.9 (4–11) 7.1 (4–11)
7.5 (6–10) 7.4 (6–9)
p = .87 p = .62
6.8 (4–10) 6.6 (4–10)
8.1 (7–10) 7.8 (5–10)
p = .86 p = .70
6.8 (4–10) 6.6 (4–10)
8.2 (7–11) 8.1 (7–10)
p = .79 p = .74
ogression; VEGF, vascular endothelial growth factor.
Bergmann et al. BMC Cancer  (2015) 15:303 Page 9 of 10of the noninterventional design (observation of routine
procedures), assessment and assessment times cannot be
standardized for study purposes. This is different than in
interventional trials, in which standardized assessments
are performed at predefined intervals. However, results
of the current study are more representative of the
effectiveness of everolimus in daily practice than are results
from interventional trials because there was no comparable
patient selection in interventional designs.
Conclusions
This noninterventional study reflects the routine clinical
use of everolimus in a large sample of patients with
mRCC. Favorable efficacy and safety were shown for
patients treated with everolimus after previous therapy
with one VEGF-targeted agent. Results of this study
confirm everolimus as one of the standard options in
second-line therapy for patients with mRCC.
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